A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. We have developed and manufacture the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The GentleWave System is a Class II device and has received 510(k) clearance from the United States Food and Drug Administration (the “FDA”) for preparing, cleaning, and irrigating teeth indicated for root canal therapy (“RCT”). Our initial focus is on leveraging the GentleWave System to transform RCT by addressing the limitations of conventional methods. The key components of our GentleWave System are a sophisticated and mobile console and pre-packaged, sterilized, single-use procedure instruments (“PIs”).
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 32M | 32M | 35M | 42M | 33M | 23M |
| Net Income | 0 | - | - | -57M | -48M | -47M |
| EPS | $-59.03 | $-59.03 | $-129.63 | $-50,800.00 | $-340,800.00 | $-1,560,800.00 |
| Free Cash Flow | -25M | -25M | -47M | -62M | -49M | -39M |
| ROIC | 0.0% | - | - | -48.1% | -49.2% | -44.4% |
| Gross Margin | 37.4% | 37.4% | 13.5% | 25.2% | 25.1% | 16.6% |
| Debt/Equity | 0.00 | 2.78 | 1.31 | 0.45 | 0.37 | -0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -29M | -29M | -59M | -58M | -44M | -43M |
| Operating Margin | -92.6% | -92.6% | -171.1% | -139.7% | -133.8% | -183.3% |
| ROE | 0.0% | - | - | -69.6% | -67.3% | - |
| Shares Outstanding | 0M | 0M | 0M | 0M | 0M | 0M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 23M | 33M | 42M | 35M | 32M | 32M |
| Gross Margin | 16.6% | 25.1% | 25.2% | 13.5% | 37.4% | 37.4% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -43M | -44M | -58M | -59M | -29M | -29M |
| Op. Margin | -183.3% | -133.8% | -139.7% | -171.1% | -92.6% | -92.6% |
| Net Income | -47M | -48M | -57M | N/A | N/A | 0 |
| Net Margin | -199.8% | -146.1% | -137.0% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -44.4% | -49.2% | -48.1% | N/A | N/A | 0.0% |
| ROE | N/A | -67.3% | -69.6% | N/A | N/A | 0.0% |
| ROA | -61.3% | -42.0% | -41.6% | N/A | N/A | 0.0% |
| Cash Flow | ||||||
| Op. Cash Flow | -39M | -49M | -61M | -46M | -25M | -25M |
| Free Cash Flow | -39M | -49M | -62M | -47M | -25M | -25M |
| Owner Earnings | -42M | -52M | -70M | -54M | -30M | -30M |
| CapEx | 916K | 638K | 1.4M | 929K | 161K | 161K |
| Maint. CapEx | 2.1M | 1.4M | 1.1M | 1.1M | 288K | 288K |
| Growth CapEx | 0 | 0 | 304K | 0 | 0 | 0 |
| D&A | 2.1M | 1.4M | 1.1M | 1.1M | 288K | 288K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.6M | 2.4M | 7.5M | 7.3M | 4.8M | 4.8M |
| Debt Repayment | 5.1M | 0 | 0 | 0 | 25M | 25M |
| Balance Sheet | ||||||
| Net Debt | 5.0M | -58M | -55M | -9.4M | 2.8M | 0 |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | 28M | 26M | 37M | 12M | 3.6M | 3.6M |
| Debt/Equity | -0.11 | 0.37 | 0.45 | 1.31 | 2.78 | 0.00 |
| Interest Coverage | -10.8 | -10.5 | -18.0 | -9.2 | -5.4 | -5.4 |
| Equity | -254M | 72M | 82M | 28M | 5.2M | 5.2M |
| Total Assets | 76M | 115M | 137M | 78M | 31M | 31M |
| Total Liabilities | 49M | 43M | 55M | 50M | 26M | 26M |
| Intangibles | 8.5M | 8.5M | 8.5M | N/A | N/A | N/A |
| Retained Earnings | -264M | -312M | -369M | -430M | -458M | -458M |
| Working Capital | 18M | 84M | 104M | 30M | 7.9M | 7.9M |
| Current Assets | 59M | 99M | 121M | 65M | 28M | 28M |
| Current Liabilities | 41M | 15M | 17M | 35M | 20M | 20M |
| Per Share Data | ||||||
| EPS | -1,560,800.00 | -340,800.00 | -50,800.00 | -129.63 | -59.03 | -59.03 |
| Owner EPS | -64,050.75 | -41,438.77 | -61,980.45 | -127.41 | -69.64 | -69.64 |
| Book Value | -384,742.47 | 56,985.32 | 72,976.58 | 66.49 | 12.15 | 12.15 |
| Cash Flow/Share | -58,408.98 | -38,435.42 | -54,381.38 | -107.77 | -57.68 | 0.67 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.0M | 0.0M | 0.0M | 0.4M | 0.4M | 0.4M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.0 | 0.0 | 0.6 | 0.1 | 0.0 |
| Price/Sales | N/A | 0.1 | 0.0 | 3.1 | 0.2 | 0.0 |
| FCF Yield | N/A | -3176.2% | -15527.6% | -259.3% | -4292.5% | -17592.6% |
| Market Cap | N/A | 1.6M | 402K | 18M | 578K | 141K |
| Avg. Price | N/A | 1,846.44 | 584.21 | 250.73 | 17.13 | 0.33 |
| Year-End Price | N/A | 1,226.00 | 358.00 | 42.40 | 1.35 | 0.33 |
Sonendo, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 23.5%.
Sonendo, Inc. (SONX) has a 5-year average return on invested capital (ROIC) of -47.2%. This is below average and may indicate limited pricing power.
Sonendo, Inc. (SONX) has a market capitalization of $141K. It is classified as a small-cap stock.
Sonendo, Inc. (SONX) does not currently pay a regular dividend.
Sonendo, Inc. (SONX) operates in the Dental Equipment & Supplies industry, within the Healthcare sector.
Sonendo, Inc. (SONX) reported annual revenue of $32 million in its most recent fiscal year, based on SEC EDGAR filings.
Sonendo, Inc. (SONX) generated $-25 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Sonendo, Inc. (SONX) has a debt-to-equity ratio of 2.78. This indicates higher leverage, which may increase financial risk.
Sonendo, Inc. (SONX) reported earnings per share (EPS) of $-59.03 in its most recent fiscal year.
Sonendo, Inc. (SONX) has a 5-year average gross margin of 23.5%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 5 years of financial data for Sonendo, Inc. (SONX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sonendo, Inc. (SONX) has a book value per share of $12.15, based on its most recent annual SEC filing.